Etamsylate Raw Material Etamsylate Powder

CAS:2624-44-4

MF: C10H17NO5S

MW: 263.31

EINECS: 220-090-7

Specification​: 99% min Etamsylate Powder

Sample: Etamsylate Powder

Packaging:1kg/bag, 25kg/drum

Brand: Henrikang

Appearance: White Powder

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

Etamsylate Powder Usage and Synthesis.

Etamsylate can increase the number, aggregation and adhesion of platelets and promote the release of coagulant active substances from platelets. It can also accelerate the contraction of blood clots and shorten the clotting time, as well as enhance capillary resistance and reduce capillary permeability.

Used for the prevention and treatment of bleeding before surgery. Also used for bleeding caused by platelet insufficiency or other causes of bleeding, such as gastrointestinal bleeding, cerebral haemorrhage and urinary tract bleeding. Intravenous LD50 in rats is 800-1350 mg/kg.

Etamsylate is indicated for the prevention and treatment of surgical bleeding, thrombocytopenic purpura or anaphylactic purpura and other causes of bleeding, such as cerebral haemorrhage, gastrointestinal haemorrhage, urinary tract haemorrhage, fundus haemorrhage, gum haemorrhage and epistaxis, etc. It can be used in conjunction with other haemostatic drugs, such as aminomethylenic acid and vitamin K.

Uses and functions of Etamsylate.

Etamsylate can enhance platelet function, reduce capillary permeability, reduce blood exudation, showing haemostatic effect, also can increase the number of platelets in the blood, enhance their aggregation and adhesion, promote the release of coagulant active substances, shorten the coagulation time, accelerate the contraction of blood clot.

Intravenous polymer plasma expanders should be injected after the use of this product and not before, because dextrose etc. inhibit platelet aggregation, prolong bleeding and coagulation time, theoretically antagonistic to this product.

It should not be mixed with aminocaproic acid injection to avoid poisoning; it should not be paired with alkaline drugs.

Pharmacological Effects of Etamsylate Raw Materials.

Etamsylate can increase the number of platelets and enhance their aggregation and adhesion, promote the release of coagulant active substances from platelets, shorten the clotting time and accelerate the contraction of blood clots.

In addition, it also has the effect of enhancing capillary resistance, reducing its permeability and decreasing blood exudation. The hemostatic effect of this product is rapid, the effect reaches the peak 1 hour after intravenous injection, and the efficacy can be maintained for 4 to 6 hours.

Production method of Etamsylate Raw Powder.

Now the production methods of Etamsylate in the market are benzoquinone method, in which benzoquinone method is to pass sulfur dioxide in the solution of diethylamine, ethanol and water, and firstly make diethylamine sulphite salt, and then add benzoquinone into diethylamine sulphite salt solution under low temperature, and then distill and recycle the ethanol under reduced pressure after the reaction is finished and precipitate the crude product after cooling, and then decolorize the product by adding sodium bisulphite and activated carbon into the water or diluted ethanol to purify the product. The product is refined.

The disadvantages of this process are: due to the incomplete reaction of p-benzoquinone, coupled with the solubility of phenolsulfonyl ethylamine in water and ethanol, making the product yield is low, generally not more than 40%, and p-benzoquinone price is high, the use of sulphur dioxide there is a problem with the absorption of tail gas and so on.

Also on the market there is the use of chlorosulfonic acid as a sulfonation agent, before sulfonation so that p-benzoquinone and organic solvents azeotropic dehydration to anhydrous, but this method uses organic solvents, pollution of the environment, which in the process of the sulfonation reaction of hydrogen chloride gas, pollution of the environment.